title: Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
abstract: In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an important role in the pathogenesis and survival advantage in hematologic malignancies, such as leukemia, lymphoma, and myeloma. The objectives of the present review, hence, are to describe the current knowledge on the PI3K pathway and its isoforms, and to summarize preclinical and clinical studies using PI3K inhibitors, focusing on the advances made in hematologic malignancies.
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.affiliation: Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Meera
authors.initials: M
authors.lastname: Iyengar
authors.affiliation: Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Kuritzky
authors.affiliation: Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI, USA.
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Bishop
keywords: inhibitors; leukemia; lymphoma; myeloma; phosphatidylinositol-3-kinase pathway